The news:Half of US pharmaceuticals launched in 2023 underperformed their first-year forecasts, while 39% overperformed, according to an analysis from Trinity Life Sciences.
Trinity compared the sales performance ofnew product launches relative to their pre-launch first-year revenue forecasts.
You've read 0 of 2 free articles this month.
Get more articles - create your free account today!